APOC3, apolipoprotein C3, 345

N. diseases: 153; N. variants: 15
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C3151467
Disease: Apolipoprotein C-III Deficiency
Apolipoprotein C-III Deficiency
0.610 GeneticVariation disease BEFREE D25V apolipoprotein C-III is a new human amyloidogenic protein and the first conferring cardioprotection even in the unfavourable context of renal failure, extending the evidence for an important cardiovascular protective role of apolipoprotein C-III deficiency. 26790392 2016
CUI: C0020443
Disease: Hypercholesterolemia
Hypercholesterolemia
0.460 GeneticVariation disease BEFREE Hypercholesterolemia is associated with the apolipoprotein C-III (APOC3) genotype in children receiving HAART: an eight-year retrospective study. 22848358 2012
CUI: C0020443
Disease: Hypercholesterolemia
Hypercholesterolemia
0.460 GeneticVariation disease BEFREE Multivariate logistic regression analysis with adjustment for age, body mass index, and the prevalence of smoking, hypertension, diabetes mellitus, and hyperuricemia revealed that three polymorphisms [994G --> T (Val279Phe) in the platelet-activating factor acetylhydrolase gene, 242C --> T (His72Tyr) in the NADH/NADPH oxidase p22 phox gene, and 1100C --> T in the apolipoprotein C-III gene] were significantly associated with CAD in men with hypercholesterolemia. 14709372 2004
CUI: C0020443
Disease: Hypercholesterolemia
Hypercholesterolemia
0.460 Biomarker disease BEFREE Vitamin D supplementation significantly increased total cholesterol, triglycerides, very-low-density lipoprotein (VLDL) triglycerides, low-density lipoprotein (LDL) triglycerides, high-density lipoprotein (HDL) triglycerides, apolipoprotein B (ApoB), LDL-ApoB, ApoCII, ApoCIII, phospholipids, and ApoE (P < .05 for all). 29653812 2019
CUI: C0020443
Disease: Hypercholesterolemia
Hypercholesterolemia
0.460 Biomarker disease BEFREE This study shows the relevance of polymorphisms in APOB (odds ratio (OR), 1.17; 95% confidence interval (95% CI), 0.74-1.85), APOC3 (OR, 1.33; 95% CI, 0.82-2.17) and APOE (OR, 1.75; 95% CI, 1.09-2.80), as genetic risk markers for hypercholesterolemia; polymorphisms in ACE (OR, 1.68; 95% CI, 0.32-8.77) and AGT (OR, 1.74; 95% CI, 0.97-3.14) for hypertension; and in APOE*3/*4 (OR, 2.06; 95% CI, 1.70-2.51) and APOE*4/*4 (OR, 3.08; 95% CI, 1.85-5.12) as unambiguous markers of dementia. 29081697 2017
CUI: C0020443
Disease: Hypercholesterolemia
Hypercholesterolemia
0.460 Biomarker disease BEFREE About 80 genes are associated with hypercholesterolemia but only pharmaceuticals that inhibit cholesteryl ester transfer protein (CETP), angiopoietin-related protein 3 (ANGPTL3), and apolipoprotein C-III (apoC-III) have recently been tested in clinical trials. 29356705 2018
CUI: C0020443
Disease: Hypercholesterolemia
Hypercholesterolemia
0.460 Biomarker disease BEFREE Hypercholesterolemics, in contrast, were distinguished from the normolipidemic group by 2-fold higher concentrations of apoB lipoproteins without apoE or apoC-III (E(-)C-III(-)), mainly LDL, which had high cholesterol content. 11483625 2001
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.400 Biomarker group BEFREE In addition, apoC-III has also more recently been identified as an important risk factor for cardiovascular disease. 31111320 2019
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.400 AlteredExpression group BEFREE Mixed dyslipidemia, characterized by elevated triglyceride and apoC-III levels and low HDL cholesterol level, with or without elevated LDL cholesterol, increases cardiovascular disease risk and is commonly treated with combined statin and fibrate therapy. 22236405 2012
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.400 AlteredExpression group BEFREE A high level of APOC3 expression is an independent risk factor for some lipid metabolism-related diseases, such as cardiovascular disease (CVD), nonalcoholic fatty liver disease (NAFLD) and atherosclerosis (AS). 29555504 2018
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.400 Biomarker group BEFREE Is APOC3 the driver of cardiovascular disease in people with type I diabetes mellitus? 31449060 2019
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.400 GeneticVariation group BEFREE Increasing evidence has shown that loss-of-function mutations in APOC3 is associated with reduction in plasma triglycerides levels and will confer a benefit in patients at high risk for cardiovascular disease. 27624799 2016
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.400 Biomarker group BEFREE Here, we review the pathophysiological role of apoC-III in TG metabolism and the evidence supporting this apolipoprotein as an emerging target for hypertriglyceridemia (HTG) and associated cardiovascular disorders. 26435212 2015
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.400 GeneticVariation group BEFREE Conclusions HDL particles of larger size and higher concentrations of large HDL and of HDL without apolipoprotein C-III were associated with lower CVD risk, with risk estimates seemingly stronger among participants with lower eGFR. 31818211 2019
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.400 GeneticVariation group BEFREE Therefore, there appears to be a need for effective TG-lowering agents.<b>Areas covered</b>: This review presents the most recent advances in hypertriglyceridemia treatment; specifically, it discusses the results of clinical trials and critically comments on apolipoprotein C-III inhibitors, angiopoietin-like 3 inhibitors, alipogene tiparvovec, pradigastat, pemafibrate and novel formulations of omega-3 fatty acids.<b>Expert opinion</b>: In the era of extreme lowering of LDL-C levels with several agents, there seems to be space for novel therapeutic options to combat parameters responsible for residual CVD risk, among which are elevated TGs. 31738617 2020
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.400 Biomarker group BEFREE Antisense inhibition of apoC-III in preclinical models and in a phase I clinical trial with healthy subjects produced potent, selective reductions in plasma apoC-III and triglyceride, 2 known risk factors for cardiovascular disease. 23542898 2013
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.400 Biomarker group BEFREE Furthermore, apoC-III and ANGPTL3, both of which are now known to associate with increased atherosclerotic cardiovascular diseases, were enriched in patients with CETP-D compared with normolipidemic subjects (35.9 ± 5.3 vs 27.1 ± 3.7, 2.3 ± 1.1 vs 0.4 ± 1.1, respectively; P < .01). 30745272 2020
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.400 Biomarker group BEFREE APOC3 is an important molecule in lipid metabolism that is closely associated with hyperlipidemia and an increased risk of developing CVD. 27619170 2016
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.400 GeneticVariation group BEFREE To explore the potential usefulness of screening for genetic predictors of cardiovascular disease, we surveyed BioVU, the Vanderbilt University Medical Center's biorepository linked to de-identified electronic health records (EHRs), for APOC3 19X mutations among adult European American patients (> 45 and > 55 years of age for men and women, respectively) with the lowest percentile of TG levels. 30255797 2018
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.400 GeneticVariation group BEFREE When put in the context of studies demonstrating significant protection from cardiovascular events in individuals with loss of function variants in the APOC3 gene, our results provide strong evidence that therapies which increase the efficiency of conversion of VLDL to LDL, thereby reducing remnant concentrations, should reduce the risk of cardiovascular disease. 30580564 2019
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.400 Biomarker group BEFREE Apolipoprotein C-III has been referred to as an important participant in the metabolism of triglyceride-rich lipoproteins, leading to hypertriglyceridemia and thereafter cardiovascular disease. 27770802 2016
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.400 Biomarker group BEFREE Because serum levels of APOC3 predicted incident CVD events in the CACTI study, inhibiting APOC3 might reduce CVD risk in T1DM patients. 31295146 2019
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.400 Biomarker group BEFREE ApoCIII and triglyceride (TG)-rich lipoproteins (TRL), particularly, large TG-rich lipoproteins particles, have been described as important mediators of cardiovascular disease (CVD) risk. 31247940 2019
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.400 Biomarker group BEFREE Apolipoprotein C-III (apo C-III) is a marker of cardiovascular disease risk associated with triglyceride (TG)-rich lipoproteins. 15576429 2005
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.400 GeneticVariation group BEFREE Loss-of-function mutations in APOC3 were associated with low levels of triglycerides and a reduced risk of ischemic cardiovascular disease. 24941082 2014